Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Trial details
- Registry ID
- NCT04480840
- Drugs studied
- PLN-74809
TrialRedline tracks 5 clinical trials sponsored by Pliant Therapeutics, Inc.: 5 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)NCT04480840 | PLN-74809 | Completed | 2024-02-26Actual |
| Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)NCT05621252 | PLN-74809 | Completed | 2023-12-27Actual |
| Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisNCT04396756 | PLN-74809 | Completed | 2023-02-01Actual |
| Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/NCT04072315 | Knottin tracer, PLN-74809 | Completed | 2022-06-27Actual |
| Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisNCT06097260 | PLN-74809 | Terminated | 2025-04-04Actual |
Names as written in the registry records.
NCT06097260 · Pliant Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To characterize the effect of bexotegrast versus placebo on the change in forced vital capacity (FVC) in participants with idiopathic pulmonary fibrosis (IPF). After: Measure: Change From Baseline in Forced Vital Capacity at Week 52.